Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)

Running, not enrolling · Phase 2

Conditions studied: Advanced Cancer, Metastatic Cancer, Malignant Neoplasm of Lung

In brief

This study will evaluate the efficacy of two dosing regimens of adagrasib (600 mg BID versus 400 mg BID) in patients with NSCLC with KRAS G12C mutation.

Key facts

Study ID
NCT05853575
Run by
Mirati Therapeutics Inc.
People needed
200
Starts
2024-02-01
Expected to finish
2026-11-30
Last updated by the study team
2026-08-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.